Oxcia is a clinical stage drug development company with two DDR (DNA Damage and Repair) drug candidates targeting cancer and fibrosis. DDR is an emerging and prioritized scientific area with numerous big pharma companies investing in the field and several recent large M&A-deals. The proceeds will be used to finance finalization of two clinical phase I studies with read-out in 2021.

We thank Oxcia for the vote of confidence and congratulate on the successful transaction!